Purchase this article with an account.
Tsutomu Igarashi, Koichi Miyake, Maika Kobayashi, Kazuhisa Takahashi, Noriko Miyake, Osamu Iijima, Kenji Nakamoto, Yukihiko Hirai, Takashi Shimada, Hiroshi Takahashi; Tyrosine-mutated AAV2 mediated BDNF gene therapy attenuates retinal ischemic injuries in rats. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3320.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To examine the ability of brain-derived neurotrophic factor (BDNF) using triple mutant adeno-associated viral (AAV) type 2 vector on retinal ischemia reperfusion injury.
Retinal ischemia was induced in rats by raising intraocular pressure (IOP) to 110 mm Hg two weeks after gene delivery. The neuroprotective effects of BDNF were evaluated by determining the preservation of the inner retina thickness and the cell counts in the cell counts in the retinal ganglion cell (RGC) layer one week after reperfusion. In addition, electroretinograms (ERGs) were performed to determine the functionality of the retina.
Gene delivery significantly improved the recovery of retinal thickness (No treatment; 78µm ± 3.6, Control; 42µm ± 10.3, AAV-BDNF; 77µm ± 8.1) and rescued b-wave (No treatment; 975µV ± 191, Control; 396µV ± 231, AAV-BDNF; 882µV ± 155).
Triple mutant AAV type 2 vector mediated BDNF extremely protected rat retina from ischemia-reperfusion injury.
This PDF is available to Subscribers Only